Related Experiment Video
Updated: Jun 20, 2026
Microvascular Decompression: Salient Surgical Principles and Technical Nuances
Published on: July 5, 2011
Microvascular decompression for trigeminal neuralgia in the elderly: long-term treatment outcome and comparison with
Thomas Günther1, Venelin M Gerganov, Lennart Stieglitz
1Gemeinschaftspraxis für Neurochirurgie, Hildesheim, Germany.
Objective:
Multiple studies have proved that microvascular decompression (MVD) is the treatment of choice in cases of medically refractory trigeminal neuralgia (TN). In the elderly, however, the surgical risks related to MVD are assumed to be unacceptably high and various alternative therapies have been proposed. We evaluated the outcomes of MVD in patients aged older than 65 years of age and compared them with the outcomes in a matched group of younger patients. The focus was on procedure-related morbidity rate and long-term outcome.
Methods:
This was a retrospective study of 112 patients with TN operated on consecutively over 22 years. The main outcome measures were immediate and long-term postoperative pain relief and neurological status, especially function of trigeminal, facial, and cochlear nerves, as well as surgical complications. A questionnaire was used to assess long-term outcome: pain relief, duration of a pain-free period, need for pain medications, time to recurrence, pain severity, and need for additional treatment.
Results:
The mean age was 70.35 years. The second and third branches of the trigeminal nerve were most frequently affected (37.3%). The mean follow-up period was 90 months (range, 48-295 months). Seventy-five percent of the patients were completely pain free, 11% were never pain free, and 14% experienced recurrences. No statistically significant differences existed in the outcome between the younger and older patient groups. Postoperative morbidity included trigeminal hypesthesia in 6.25%, hypacusis in 5.4%, and complete hearing loss, vertigo, and partial facial nerve palsy in 0.89% each. Cerebrospinal fluid leak and meningitis occurred in 1 patient each. There were no mortalities in both groups.
Conclusion:
MVD for TN is a safe procedure even in the elderly. The risk of serious morbidity or mortality is similar to that in younger patients. Furthermore, no significant differences in short- and long-term outcome were found. Thus, MVD is the treatment of choice in patients with medically refractory TN, unless their general condition prohibits it.
Insights
Microvascular decompression (MVD) for trigeminal neuralgia (TN) is safe and effective in elderly patients over 65. Outcomes and risks are comparable to younger patients, making MVD a suitable treatment choice.
Area of Science:
- Neurosurgery
- Neurology
Background:
- Microvascular decompression (MVD) is the standard treatment for medically refractory trigeminal neuralgia (TN).
- Concerns exist regarding the safety and efficacy of MVD in elderly patients due to assumed higher surgical risks.
Purpose of the Study:
- To evaluate the outcomes of MVD in patients aged 65 and older with TN.
- To compare the procedure-related morbidity and long-term outcomes of elderly patients with a matched group of younger patients.
Main Methods:
- Retrospective study of 112 consecutive TN patients operated on over 22 years.
- Outcome measures included immediate and long-term pain relief, neurological status, and surgical complications.
- Long-term outcomes were assessed via questionnaire, evaluating pain relief, recurrence, and medication needs.
Main Results:
- The mean age of elderly patients was 70.35 years; the second and third trigeminal nerve branches were most affected.
- 75% of all patients achieved complete pain relief, with no statistically significant difference in outcomes between younger and older groups.
- Postoperative morbidity was low, with no mortalities in either group. Comparable outcomes and low morbidity were observed in elderly patients.
Conclusions:
- Microvascular decompression (MVD) is a safe and effective procedure for medically refractory trigeminal neuralgia (TN), even in patients over 65.
- The risks of serious morbidity and mortality are similar to those in younger patients.
- MVD should be considered the treatment of choice for elderly patients with TN, provided their general health permits the procedure.
Related Concept Videos
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...